Aikido pharma files patent application for the use of ketamine to treat alzheimer's disease

New york, june 23, 2021 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki) ("aikido" or the "company") today announced that the company has filed a provisional patent application for the use of ketamine and peptides to treat alzheimer's disease.  the company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.
DOMH Ratings Summary
DOMH Quant Ranking